V930 First in Man (FIM) Study
This study has been completed.
Information provided by:
First received: November 7, 2005
Last updated: May 19, 2009
Last verified: May 2009
To determine the safety/tolerability, and immunogenicity of an experimental vaccine given as intramuscular injections followed by electrostimulation in cancer patients.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase I Study to Evaluate the Safety/Tolerability and Immunogenicity of V-930 in Patients With Cancers Expressing HER-2 and/or CEA|
Resource links provided by NLM:
Further study details as provided by Merck:
Contacts and Locations